Related Experiment Video
Updated: May 23, 2026
05:28
A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
RAMPs as drug targets.
Patrick M Sexton1, David R Poyner, John Simms
1Department of Pharmacology, Monash University, Victoria, Australia.
Advances in Experimental Medicine and Biology
|March 22, 2012
Summary
Receptor activity-modifying proteins (RAMPs) influence G protein-coupled receptor (GPCR) function and cell surface trafficking. Targeting RAMPs offers novel therapeutic strategies for diseases involving RAMP-interacting GPCRs.
Area of Science:
- Molecular and Cellular Biology
- Pharmacology
- Neuroscience
Background:
- Receptor activity-modifying proteins (RAMPs) are key regulators of G protein-coupled receptor (GPCR) function.
- RAMPs modulate GPCR pharmacology, signaling, and cell surface trafficking.
- RAMP-GPCR interactions present potential therapeutic targets.
Purpose of the Study:
- To explore the role of RAMPs in GPCR regulation.
- To highlight the therapeutic potential of targeting RAMPs and RAMP-interacting GPCRs.
- To discuss the development of small molecule antagonists for RAMP-GPCR complexes.
Main Methods:
- Review of existing literature on RAMPs and GPCRs.
- Analysis of RAMP-mediated regulation of receptor function.
- Examination of drug development strategies targeting RAMPs.
Main Results:
- RAMPs significantly alter GPCR pharmacology and signaling pathways.
- RAMPs control the trafficking of GPCRs to and from the cell surface.
- Small molecule antagonists targeting RAMP1/calcitonin receptor-like receptor complexes are under development for migraine treatment.
Conclusions:
- RAMPs are crucial modulators of GPCR activity and trafficking.
- Targeting RAMPs offers a promising avenue for novel drug development.
- RAMP antagonists show potential for treating conditions like migraine headaches.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.